BTC$59,604.00-1.82%
ETH$1,567.46-2.24%
USDT$0.9986+0.02%
BNB$551.55-2.46%
USDC$0.9997-0.01%
XRP$1.04-2.40%
SOL$71.21-1.98%
TRX$0.3231+0.78%
FIGR_HELOC$1.04+1.53%
HYPE$62.31-2.87%
DOGE$0.073-4.07%
USDS$0.9996+0.02%
RAIN$0.0155-0.85%
LEO$9.44+0.69%
ZEC$388.97-5.35%
XMR$314.72+0.20%
BTC$59,604.00-1.82%
ETH$1,567.46-2.24%
USDT$0.9986+0.02%
BNB$551.55-2.46%
USDC$0.9997-0.01%
XRP$1.04-2.40%
SOL$71.21-1.98%
TRX$0.3231+0.78%
FIGR_HELOC$1.04+1.53%
HYPE$62.31-2.87%
DOGE$0.073-4.07%
USDS$0.9996+0.02%
RAIN$0.0155-0.85%
LEO$9.44+0.69%
ZEC$388.97-5.35%
XMR$314.72+0.20%
Danaher stock fell after the company announced a $9.9B all-cash deal to buy Masimo, expanding its diagnostics and patient monitoring business.
Danaher Corporation has outperformed market expectations in Q4 2025, reporting an EPS of $2.23 and revenue of $6.84 billion, both exceeding anticipated figures.
Danaher reported Q3 revenue of $6.1 billion and EPS of $1.89, topping estimates and maintaining a positive full-year outlook.
Danaher Corporation's second quarter results for 2025 show a notable increase in revenue and net earnings, exceeding analyst expectations.
Danaher Corporation (NYSE: DHR) reported strong Q3 results with net earnings of $818 million.
Danaher Corporation reported solid financial results for the Q2 2024, with net earnings of $907 million and revenues totaling $5.7 billion.
Danaher Corporation exceeded market expectations in Q1 2024, reporting net earnings of $1.1 billion and non-GAAP diluted net earnings per common share of $1.92.
Danaher Corporation announced strong Q4 results, outperforming expectations.